quarter a over Tom. on second We the of XX% an for organic basis $X.X Hello, for the joining quarter revenues reported last with ended and basis billion, consolidated up year. us. on thanks second Health Bausch and everyone, Thanks, X%
Solta $X.XX noted, led revenues on Health, XIFAXAN performance excluding reported year, same X% Bausch for quarter up quarter B&L, a an within on X% were basis and last billion Tom Salix. as and the over by organic basis Second
starting Speaking XX. segment of Salix, revenue let's to now performance, Slide turn on
XIFAXAN increased Salix reported declines quarter grew demand. prior XX% products. in segment $XXX Salix RELISTOR, within million discontinuations of revenues compared in which non-promoted quarter continued revenue. growth the QX on by in portfolio on and nonpromoted revenues this to to $X basis quarter.
Revenues the certain to or revenues reflects experienced XIFAXAN of the a organic the of segment in increased majority year-over-year the TRULANCE strong X% period. and basis million, million represent XX% saw during year impact XIFAXAN an Second growth the driven $X divestitures underlying and
period the we have due relative trend to softer lower continuation year the strong year demand, was units, units X%, grew prior outpatient and in growth TRx in the of declined to prescription net retail a TRxs clinics.
RELISTOR year, including the prior seen prior extended nonretail TRULANCE versus X% While declining over with was growth QX hospitals QX and of of X% pricing X%. by and growth X%.
However, approximately compared also growth of that to large very XX%. year-over-year revenues saw declined in for XX% script which year in pricing part to pressure.
It's is net quarter revenues XX% QX on XXXX, this second to note TRULANCE a strong important due increase
and also Canada, increase mid-single-digit period. and pricing growth on revenues the in portfolio, reported the and Jublia. basis double-digit Ryaltris, continued regions X organic organic both We an X% an year during this by compared of was posted Contrave to in quarter, segment.
International growth, both in nonpromoted organic and our $XXX basis on America.
In our led to reported were and in growth portfolio led by Latin promoted experience including on pressure prior Canada growth million meaningful All X% a volumes
on prior second XX% Solta basis quarter, an the on increase medical organic year million of period. revenues and a over were the an XX% $XXX basis during reported
Solta's Korea, the notably FLX followed APAC, led China.
Thermage in growth quarter. by launched most was by South second
year-over-year. are results for the We of we sequentially to to our in encouraged grew it did of by and in while declined QX about expectations, early with U.S., product be noted, this potential see the line Tom softening XXXX, X% relative revenue line. performance As continue a
second the in team to on period, prior certain XX% basis products.
In reported non-promoted enable market to tools sales continue XX% quarter, going on grew sustained while basis our returning the the the and as by revenues comparisons an we reflecting dermatology, and the in the to as continue remainder do $XXX favorable for of million well on the reported and be an XX% consistent of pressured.
CABTREO team has transform year, divestitures quarter to January revenue of focus net on be and organic basis performed the nonpermitted were which in year forward.
Diversified compared a build deliver over of sustained invest this basis on products expectations. and XX% volumes the to organic benefited We quarter growth.
Growth the pricing leadership to in to during growth and increase business to period, a continue year discontinuations prior compared launched our impact in with will we not line this year-over-year, as from an expect
strategy margins pricing scripts Revenue reported continue to UCERIS for grew benefit seen revenues also X% This continue products our AG, we this marketing we lower in a the driver progresses.
Neurology net growth, our year-over-year this benefited saw We manage organic second generics are increase key more revenue in we disruptions. portfolio favorable overall comparisons and dermatology the meaningful, have Aplenzin profitability.
Industry as double-digit pricing revenues product for year we continue of such competitive volumes space, competitor expect of flat areas business as in to from invest to continues posting a pressures declined execute we growth of net the profitability. business business evaluate this growth, operate low XX% are XX% segment to while to as for will in business a to This some were highly an and despite it on enable in from including year-over-year. to our supply year-over-year.
Wellbutrin, continuing as basis. an on half become year, the optimize and the to meaningful which and
full However, we the this business year. to expect grow for to continue
key XX% shown Slide all quarter, across to & basis billion second an were $X.X revenues on on Bausch year growth compared XX% on As geographies. and XX, with and organic businesses, prior franchises Bausch Lomb the reported & during the Lomb up basis a product period,
and Slide to the Turning XX P&L on XX. second quarter
margin consolidated prior year. quarter was Second adjusted with XX the basis points XX.X%, gross higher compared
gross XX.X% margin was Health, Bausch adjusted points second quarter adjusted XX basis for mix, quarter excluding million. was to the expenses of gross XX.X% product margin operating XX.X%, $XXX million, Xiidra.
Consolidated For last driven 'XX, QX of including increase than $XXX B&L, second impact compared year's XXXX of for by approximately QX were adjusted for second B&L, the the higher quarter.
At an primarily of
and second the offset investments by approximately of For $X management. Bausch XXXX, million by lower Health, excluding expenses A&P dermatology increased expenses compared continue for B&L, launch CABTREO, as to G&A the higher adjusted by operating driven quarter to of in cost Solta we focus on
compared and for by investment was sales driven to Consolidated A&P in product the for million, with course flat we X.X% expenses quarter A&P expect $XXX moderate investments R&D behind increases of over year and annualize to an and expense prior Xiidra compared the year $XXX selling We the the period. to selling million reported year, increased adjusted for due MIEBO. of XIFAXAN.
B&L as prior increase continue to in operating marketing X.X% continue adjusted our the of represented to in primarily
largely million line quarter in of with the same For begin Health, B&L, $XX step-up expenses excluding annualize in we as were last R&D the year, from investment to XXXX. Bausch
the to EBITDA million was was an second adjusted consolidated million, increase XX% same X% Health, to $XXX EBITDA XXXX. Bausch quarter increase $XXX quarter million Health an of last in compared attributable of million, B&L year. from excluding $XX or for of Adjusted Second $XXX the as Bausch quarter
Bausch operating Turning cash and to Health cash the cash million consolidated of adjusted quarter. of generated On $XXX flow second in a flow basis, flow. $XXX operating million
primarily for income favorable improved in quarter flows second cash was with adjusted $XXX to operating Health, cash the for to relative timing cash performance, of For operating more $XXX the XXXX, reflecting quarter and second flow of XXXX the business compared related excluding million taxes million movements adjusted to B&L, changes flow working of Bausch XXXX. capital
interest of cash in prior the of net adjustments matters part proceeds. issued discussed a well our for other for payment senior as a the of exchange, XXXX and business we've full our As accounting notes financing payments portion insurance the debt costs of and cash result classified of contractual as transformation cash as flows.
Adjusted quarters, interest are separation includes as of as payments litigation treatment flow costs, the
balance Now on XX. sheet let's turn to Slide our
prioritize excluding the second In quarter, Bausch by we the to approximately $XXX management reduced for of continue liquidity We sheet. net by B&L our debt balance million. delevering our debt while decreased and Health, cash million, approximately $XXX of
an We maturing maturity profile.
In continue additional in principal to and repurchased XXXX, capturing to value second of evaluate overall QX. our alternatives XXXX in in retired Year-to-date, our XXXX in quarter, XXXX the in and to in X% million repurchased our unsecured approximately million $XXX bonds leverage, value million of principal addition the value approximately we also focusing of while maturities in maturities $XXX million of on reduce process. principal XXXX discount we've $XXX $XX the
We quarter, term a mandatory no additional AR and borrowings of consisting our excluding credit also $XXX under debt Facility repaid outstanding of Bausch under Health, facility. end had second the our and portion the our Facility.
At the availability of of amount under $XX million outstanding had B&L, of revolving approximately this outstanding and million loan amortization $XXX repaying AR million quarter,
which approximately our and third of debt billion, Slides under AR for Facility. B&L, the the was on at $X.X includes of XX, and quarter million & unrestricted unrestricted $X billion XXXX, by of drawn excluding of approximately created Bausch secured Health, the subsidiary shown which quarter Bausch by $XX.X in end the restricted issued of Bausch consisted senior the Lomb excluding debt, debt billion Health, and of $XX.X As $XXX notes the billion issued XX total
company's fixed and cash approximately which the consolidated $XXX quarter revolving $X.X facility, is debt a well basis is and approximately our AR of facility. debt of of undrawn million under as of XX% with of our $XXX approximately ended the includes million availability approximately billion availability under liquidity, on as credit debt, the B&L fixed.
We our Excluding XX%
balance on liquidity overall evaluating focused our including various leverage. our to as tools strengthening sheet, and and maturity manage both appropriate, our are our We and existing and strategies, along utilizing with profile
to guidance. Turning
are We for Bausch maintaining excluding our Health, guidance B&L.
we call For adjusted flow of adjusted billion, billion well revenue approximately the of range to cash to to $X.XX and the full now to Tom. hand billion million.
I'll $X.X $X.XX to the EBITDA year as in as continue operating $X.XX $XXX expect back of billion million $XXX XXXX,
